Division of Nephrology, Department of Internal Medicine, College of Medicine, Chungnam National University Hospital, Daejeon, Korea.
Department of Pathology, College of Medicine, Chungnam National University Hospital, Daejeon, Korea.
Kidney Res Clin Pract. 2013 Sep;32(3):115-20. doi: 10.1016/j.krcp.2013.07.002. Epub 2013 Sep 3.
The aim of this study was to evaluate the clinical characteristics of nondiabetic nephropathy in type 2 diabetes mellitus patients and to find a clinical significance of renal biopsy and immunosuppressive treatment in such a patient.
Renal biopsy results, clinical parameters, and renal outcomes were analyzed in 75 diabetic patients who underwent kidney biopsy at Chungnam National University Hospital from January 1994 to December 2010.
The three most common reasons for renal biopsy were nephrotic range proteinuria (44%), proteinuria without diabetic retinopathy (20%), and unexplained decline in renal function (20.0%). Ten patients (13.3%) had only diabetic nephropathy (Group I); 11 patients (14.7%) had diabetic nephropathy with superimposed nondiabetic nephropathy (Group II); and 54 patients (72%) had only nondiabetic nephropathy (Group III). Membranous nephropathy (23.1%), IgA nephropathy (21.5%), and acute tubulointerstitial nephritis (15.4%) were the three most common nondiabetic nephropathies. Group III had shorter duration of diabetes and lesser diabetic retinopathy than Groups I and II (P=0.008). Group II had the lowest baseline estimated glomerular filtration rate (P=0.002), with the greatest proportion of renal deterioration during follow-up (median 38.0 months, P<0.0001). The patients who were treated with intensive method showed better renal outcomes (odds ratio 4.931; P=0.01). Absence of diabetic retinopathy was associated with favorable renal outcome in intensive treatment group (odds ratio 0.114; P=0.032).
Renal biopsy should be recommended for type 2 diabetic patients with atypical nephropathy because a considerable number of these patients may have nondiabetic nephropathies. And intensive treatment including corticosteroid or immunosuppressants could be recommended for type 2 diabetic patients with nondiabetic nephropathy, especially if the patients do not have diabetic retinopathy.
本研究旨在评估 2 型糖尿病患者中非糖尿病性肾病的临床特征,并寻找肾活检和免疫抑制治疗在这类患者中的临床意义。
分析 1994 年 1 月至 2010 年 12 月期间在忠南国立大学医院接受肾活检的 75 例糖尿病患者的肾活检结果、临床参数和肾脏预后。
肾活检的三个最常见原因是肾病范围蛋白尿(44%)、无糖尿病视网膜病变的蛋白尿(20%)和肾功能不明原因下降(20.0%)。10 例患者(13.3%)仅有糖尿病肾病(I 组);11 例患者(14.7%)糖尿病肾病合并非糖尿病肾病(II 组);54 例患者(72%)仅有非糖尿病肾病(III 组)。膜性肾病(23.1%)、IgA 肾病(21.5%)和急性肾小管间质性肾炎(15.4%)是非糖尿病肾病的三种最常见类型。III 组的糖尿病病程较短,糖尿病视网膜病变较轻,与 I 组和 II 组相比(P=0.008)。II 组的基线估算肾小球滤过率最低(P=0.002),随访期间肾功能恶化的比例最大(中位数 38.0 个月,P<0.0001)。接受强化治疗的患者肾脏结局更好(比值比 4.931;P=0.01)。强化治疗组中无糖尿病视网膜病变与肾脏结局良好相关(比值比 0.114;P=0.032)。
对于有非典型肾病的 2 型糖尿病患者,应推荐进行肾活检,因为相当一部分患者可能患有非糖尿病性肾病。对于患有非糖尿病性肾病的 2 型糖尿病患者,包括皮质类固醇或免疫抑制剂在内的强化治疗可能是推荐的,特别是如果患者没有糖尿病视网膜病变。